24 January 2018
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
1 min read
On 23 January 2018, the Court of Justice of the European Union handed down its judgment in the Avastin – Lucentis case.
The ECJ held that the coordinated dissemination of misleading safety claims with regard to a medicine’s off-label use may constitute a serious violation of the competition rules that qualifies as a “by object” infringement and therefore allows the European Commission to dispense with the requirement to show the arrangement’s anticompetitive effects.
The judgment also contains interesting observations on product market definition in the pharmaceutical sector and can be found here.
You can read our observations on the judgment in the attached note.
Attachments:
->
News & insights
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
5 min
read
read
Briefings
Court of Justice of European Union Rules that Pay-for-Delay Patent Settlements May Restrict Competition ‘by Object’
3 February 2020
10 min
read
read
Briefings
General Court Reviews New Set of Patent Settlement Agreements In Pharmaceutical Sector (Servier and Others)
27 December 2018
